why choose us

First received: April 24, 2023

Clinical Trial: IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

Study Type: INTERVENTIONAL


Official Title: Pilot Study of an IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Brief Summary: This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer.IO102-IO103 is a novel IDO and PD-L1 peptide based immune-modulatory therapeutic.It is designed to activate the patient's own immune cells (called T-cells) to fight the tumor and stop the tumor cells escaping from the body's immune system.IO102-IO103 works to directly kill tumor cells and remove the…

Read more